Efficiency of BRCAPRO and Myriad II mutation probability thresholds versus cancer history criteria alone for BRCA1/2 mutation detection

Familial Cancer

Volumn 9, Issue 2, 2010, Pages 193-201

  Van Harssel, J J T ^a,b   Van Roozendaal, C E P ^a   Detisch, Y ^a   Brandao R D ^a,c   Paulussen, A D C ^a   Zeegers, M ^d,e   Blok, M J ^a   Gomez Garcia E B ^a,c  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d MAASTRICHT UNIVERSITY   (Netherlands)

^e Unit of Genetic Epidemiology   (United Kingdom)

Author keywords

BRCA1; BRCA2; BRCAPRO; Mutation; Myriad II; Probability model; Unclassified variants

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; DNA;

ARTICLE; BRCAPRO; CONTROLLED STUDY; DNA DETERMINATION; FAMILY HISTORY; GENE MUTATION; GENETIC VARIABILITY; HUMAN; MATHEMATICAL MODEL; MYRIAD II; NEOPLASM; ONCOGENE; PRIORITY JOURNAL; PROBABILITY;

ALGORITHMS; BRCA1 PROTEIN; BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENETIC VARIATION; HETEROZYGOTE DETECTION; HUMANS; MALE; MUTATION; PEDIGREE; PROBABILITY;

EID: 77955052702     PISSN: 13899600     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10689-009-9305-1     Document Type: Article

References (33)

1. Miki Y, Swensen J, Shattuck-Eidens D et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266(5182):66-71 (Pubitemid 24345325)
2. Wooster R, Bignell G, Lancaster J et al (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378(6559):789-792
3. Wagner T, Stoppa-Lyonnet D, Fleischmann E et al (1999) Denaturing high-performance liquid chromatography detects reliably BRCA1 and BRCA2 mutations. Genomics 62(3):369-376
4. Hogervorst FB, Nederlof PM, Gille JJ et al (2003) Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method. Cancer Res 63(7):1449-1453
5. Antoniou A, Pharoah PD, Narod S et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5):1117-1130
6. King MC, Marks JH, Mandell JB (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302(5645):643-646
7. Easton DF, Ford D, Bishop DT (1995) Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast cancer linkage consortium. Am J Hum Genet 56(1):265-271
8. Ford D, Easton DF, Stratton M et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The breast cancer linkage consortium. Am J Hum Genet 62(3):676-689
9. Thompson D, Easton D (2001) Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 68(2):410-419
10. Couch FJ, DeShano ML, Blackwood MA et al (1997) BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 336(20):1409-1415
11. Shattuck-Eidens D, Oliphant A, McClure M et al (1997) BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA 278(15):1242-1250
12. Frank TS, Manley SA, Olopade OI et al (1998) Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol 16(7):2417-2425
13. Frank TS, Deffenbaugh AM, Reid JE et al (2002) Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10, 000 individuals. J Clin Oncol 20(6):1480-1490
14. Parmigiani G, Berry D, Aguilar O (1998) Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62(1):145-158
15. Evans DG, Eccles DM, Rahman N et al (2004) A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. J Med Genet 41(6):474-480
16. Antoniou AC, Pharoah PP, Smith P, Easton DF (2004) The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer 91(8):1580-1590
17. Statement of the American Society of Clinical Oncology (1996) Genetic testing for cancer susceptibility. J Clin Oncol 14(5): 1730-1736 (discussion 1737-1740)
18. American Society of Clinical Oncology policy statement update (2003) Genetic testing for cancer susceptibility. J Clin Oncol 21(12): 2397-2406
19. Kwaliteitsinstituut voor de Gezondheidszorg CBO, Vereniging van Integrale Kankercentra. Richtlijn mammacarcinoom. Utrecht, 2007
20. National Institute for health and clinical Excellence (NICE). (2006) Familial breast cancer-NICE clinical guideline 41. www.nice.org.uk
21. Berry DA, Iversen ES Jr, Gudbjartsson DF et al (2002) BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol 20(11):2701-2712
22. James PA, Doherty R, Harris M et al (2006) Optimal selection of individuals for BRCA mutation testing: a comparison of available methods. J Clin Oncol 24(4):707-715
23. Bodmer D, Ligtenberg MJ, van der Hout AH et al (2006) Optimal selection for BRCA1 and BRCA2 mutation testing using a combination of 'easy to apply' probability models. Br J Cancer 95(6):757-762
24. Antoniou AC, Hardy R, Walker L et al (2008) Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad II and the Manchester scoring system using data from UK genetics clinics. J Med Genet 45(7):425-431
25. Lindor NM, Lindor RA, Apicella C et al (2007) Predicting BRCA1 and BRCA2 gene mutation carriers: comparison of LAMBDA, BRCAPRO, Myriad II, and modified Couch models. Fam Cancer 6(4):473-482
26. Goldgar DE, Easton DF, Deffenbaugh AM et al (2004) Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. Am J Hum Genet 75(4):535-544
27. Gómez García EB, Ambergen T, Blok MJ, van den Wijngaard A (2005) Patients with an unclassified genetic variant in the BRCA1 or BRCA2 genes show different clinical features from those with a mutation. J Clin Oncol 23(10):2185-2190
28. Gómez García EB, Oosterwijk JC, Timmermans M et al (2009) A method to assess the clinical significance of unclassified variants (UVs) in the BRCA1 and BRCA2 genes based on cancer family history. Breast Cancer Res 11(1):1-12
29. Mirkovic N, Marti-Renom MA, Weber BL et al (2004) Structurebased assessment of missense mutations in human BRCA1: implications for breast and ovarian cancer predisposition. Cancer Res 64(11):3790-3797
30. Judkins T, Hendrickson BC, Deffenbaugh AM et al (2005) Application of embryonic lethal or other obvious phenotypes to characterize the clinical significance of genetic variants found in trans with known deleterious mutations. Cancer Res 65(21): 10096-10103
31. Chenevix-Trench G, Healey S, Lakhani S et al (2006) Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance. Cancer Res 66(4):2019-2027
32. Wu K, Hinson SR, Ohashi A et al (2005) Functional evaluation and cancer risk assessment of BRCA2 unclassified variants. Cancer Res 65(2):417-426
33. Farrugia DJ, Agarwal MK, Pankratz VS et al (2008) Functional assays for classification of BRCA2 variants of uncertain significance. Cancer Res 68(9):3523-3531